Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
PODD Analyst Ratings
Strong Buy
14 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PODD Stock 12 Month Forecast
Average Price Target
$318.40
▲(23.89% Upside)
| Highest Price Target$350.00 | Average Price Target$318.40 | Lowest Price Target$266.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wolfe Research
Downgraded
04/29/25
Leerink Partners
Reiterated
04/28/25
Bank of America Securities
Reiterated
04/28/25
William Blair
Reiterated
04/28/25
Canaccord Genuity
Reiterated
04/28/25
Morgan Stanley
Reiterated
04/28/25
RBC Capital
$340→$325
Buy
26.45%
Upside
Reiterated
04/15/25
Insulet price target lowered to $325 from $340 at RBC CapitalInsulet price target lowered to $325 from $340 at RBC Capital
Jefferies
$340→$350
Buy
36.18%
Upside
Reiterated
03/03/25
Insulet's Strategic Expansion and Competitive Edge Drive Buy RatingWe recently met with mgmt inc. CEO Jim Hollingshead and continue to believe PODD is in a unique position to capture share in an infecting market. Key takes: 1) Expecting US NCS growth in T1/T2 q/q and y/y; 2) Plans to launch in 10 countries in '25 w O5; 3) Sales initiatives targeted at expanding PCPs/T2 largely done, risk retired; 4) T2 remains underappreciated and under-penetrated; PODD has a right to win there; 5) iOS w G7 in 1H, working on L3 integration. PODD emphasized its competitive moat around form factor, clinical data, and extending through manufacturing given it has invested >$1B to commercialize its patch pump at scale while maintaining quality. This moat has been reinforced by recent IP wins vs. EOFLOW (NC) and EMBC's (NC) 11/24 decision discontinue their patch program (too difficult to scale).
Bernstein
$315→$335
Buy
30.35%
Upside
Reiterated
02/24/25
Insulet's Strong Q4 2024 Performance and Promising 2025 Outlook Drive Positive Rating and Price Target IncreaseWe like the setup for 2025. Investment Implications We rate PODD Outperform with a price target of $335 (up from $315) using a P/S multiple of 8.5x (up from 8.0x to reflect increasing profitability) against our forward Q5-Q8 sales estimate of $2.94bn (previously $2.89bn), and we see upside to this valuation driven by T2D execution and margin expansion. PODD currently trades at ~8.1x sales, well below the average 14x range the stock held from 2H20 to 1H23. See our initiation report here. 2025 PODD Close Price (USD) 282.80 Price Target (USD) 335.00 289.46/160.19 SPX 6,013.13 FYE Dec Div Yield NA Market Cap (USD) (M) 19,860 EV (USD) (M) 20,286 Performance YTD 1M 6M 12M Absolute (%) 8.3 2.4 52.2 46.9 SPX (%) 2.2 (0.6) 7.0 20.7 Relative (%) 6.1 3.0 45.2 26.2 Source: Bloomberg, Bernstein estimates and analysis.
BTIG
$310
Buy
20.62%
Upside
Reiterated
02/24/25
Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), Arcutis Biotherapeutics (NASDAQ: ARQT) and Insulet (NASDAQ: PODD)
Raymond James
$294→$328
Buy
27.62%
Upside
Reiterated
02/21/25
Insulet price target raised to $328 from $294 at Raymond JamesInsulet price target raised to $328 from $294 at Raymond James
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wolfe Research
Downgraded
04/29/25
Leerink Partners
Reiterated
04/28/25
Bank of America Securities
Reiterated
04/28/25
William Blair
Reiterated
04/28/25
Canaccord Genuity
Reiterated
04/28/25
Morgan Stanley
Reiterated
04/28/25
RBC Capital
$340→$325
Buy
26.45%
Upside
Reiterated
04/15/25
Insulet price target lowered to $325 from $340 at RBC CapitalInsulet price target lowered to $325 from $340 at RBC Capital
Jefferies
$340→$350
Buy
36.18%
Upside
Reiterated
03/03/25
Insulet's Strategic Expansion and Competitive Edge Drive Buy RatingWe recently met with mgmt inc. CEO Jim Hollingshead and continue to believe PODD is in a unique position to capture share in an infecting market. Key takes: 1) Expecting US NCS growth in T1/T2 q/q and y/y; 2) Plans to launch in 10 countries in '25 w O5; 3) Sales initiatives targeted at expanding PCPs/T2 largely done, risk retired; 4) T2 remains underappreciated and under-penetrated; PODD has a right to win there; 5) iOS w G7 in 1H, working on L3 integration. PODD emphasized its competitive moat around form factor, clinical data, and extending through manufacturing given it has invested >$1B to commercialize its patch pump at scale while maintaining quality. This moat has been reinforced by recent IP wins vs. EOFLOW (NC) and EMBC's (NC) 11/24 decision discontinue their patch program (too difficult to scale).
Bernstein
$315→$335
Buy
30.35%
Upside
Reiterated
02/24/25
Insulet's Strong Q4 2024 Performance and Promising 2025 Outlook Drive Positive Rating and Price Target IncreaseWe like the setup for 2025. Investment Implications We rate PODD Outperform with a price target of $335 (up from $315) using a P/S multiple of 8.5x (up from 8.0x to reflect increasing profitability) against our forward Q5-Q8 sales estimate of $2.94bn (previously $2.89bn), and we see upside to this valuation driven by T2D execution and margin expansion. PODD currently trades at ~8.1x sales, well below the average 14x range the stock held from 2H20 to 1H23. See our initiation report here. 2025 PODD Close Price (USD) 282.80 Price Target (USD) 335.00 289.46/160.19 SPX 6,013.13 FYE Dec Div Yield NA Market Cap (USD) (M) 19,860 EV (USD) (M) 20,286 Performance YTD 1M 6M 12M Absolute (%) 8.3 2.4 52.2 46.9 SPX (%) 2.2 (0.6) 7.0 20.7 Relative (%) 6.1 3.0 45.2 26.2 Source: Bloomberg, Bernstein estimates and analysis.
BTIG
$310
Buy
20.62%
Upside
Reiterated
02/24/25
Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), Arcutis Biotherapeutics (NASDAQ: ARQT) and Insulet (NASDAQ: PODD)
Raymond James
$294→$328
Buy
27.62%
Upside
Reiterated
02/21/25
Insulet price target raised to $328 from $294 at Raymond JamesInsulet price target raised to $328 from $294 at Raymond James
Best Analysts Covering Insulet
Which Analyst Should I Follow If I Want to Buy PODD and Sell After:
1 Month
xxx
Success Rate
13/18 ratings generated profit
Average Return
+5.01%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +5.01% per trade.
3 Months
xxx
Success Rate
13/15 ratings generated profit
Average Return
+12.72%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 86.67% of your transactions generating a profit, with an average return of +12.72% per trade.
1 Year
Success Rate
11/15 ratings generated profit
Average Return
+24.63%
reiterated a buy rating 2 months ago
Copying Matthew Taylor's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +24.63% per trade.
2 Years
xxx
Success Rate
12/15 ratings generated profit
Average Return
+64.29%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +64.29% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PODD Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
0
0
0
0
0
Buy
27
28
28
25
29
Hold
2
2
1
1
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
30
29
26
32
Each month's total comprises the sum of three months' worth of ratings.
PODD Financial Forecast
PODD Stock Forecast FAQ
What is PODD’s average 12-month price target, according to analysts?
Based on analyst ratings, Insulet’s 12-month average price target is 318.40.
What is PODD’s upside potential, based on the analysts’ average price target?
Insulet has 23.89% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PODD a Buy, Sell or Hold?
Insulet has a consensus rating of Strong Buy which is based on 14 buy ratings, 3 hold ratings and 0 sell ratings.
What is Insulet’s price target?
The average price target for Insulet is 318.40. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $350.00 ,the lowest forecast is $266.00. The average price target represents 23.89% Increase from the current price of $257.01.
The highest analyst price target is $350.00 ,the lowest forecast is $266.00. The average price target represents 23.89% Increase from the current price of $257.01.
What do analysts say about Insulet?
Insulet’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of PODD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.